Liver enzymes, nonalcoholic fatty liver disease, and incident cardiovascular disease: A narrative review and clinical perspective of prospective data

@article{Ghouri2010LiverEN,
  title={Liver enzymes, nonalcoholic fatty liver disease, and incident cardiovascular disease: A narrative review and clinical perspective of prospective data},
  author={Nazim Ghouri and David Preiss and Naveed Sattar},
  journal={Hepatology},
  year={2010},
  volume={52}
}
In recent years, a strong link has been established between nonalcoholic fatty liver disease (NAFLD) and the pathogenesis of type 2 diabetes mellitus. The potential role of NAFLD in cardiovascular disease (CVD) has also attracted interest. Published studies have tended to use biochemical and imaging surrogate markers of NAFLD, such as elevated gamma glutamyl transpeptidase (GGT) and alanine aminotransferase (ALT) and fatty liver on ultrasound, when investigating associations with incident CVD… Expand
The association of liver enzymes with biomarkers of subclinical myocardial damage and structural heart disease.
TLDR
Elevated liver enzyme levels in the absence of elevated alcohol consumption may be associated with subclinical myocardial injury and the inverse association between NT-proBNP and both ALT and AST supports the recently described metabolic role of natriuretic peptides. Expand
Independent Association between Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: A Systematic Review and Meta-Analysis
TLDR
NAFLD is a strong independent predictor of cardiovascular disease and may play a central role in the cardiovascular risk of metabolic syndrome, according to the systematically searched MEDLINE, Embase, and the Cochrane Library database. Expand
Update on cardiovascular risk in nonalcoholic fatty liver disease
TLDR
Assessment and treatment of increased cardiovascular risk is important in patients with NAFLD and if not contra-indicated, pioglitazone or a glucagon-like peptide 1 agonist should be considered and may benefit both CVD risk and early liver disease. Expand
Nonalcoholic fatty liver disease as a potential risk factor of cardiovascular disease
TLDR
NAFLD is likely to be associated with an increased risk of CVD, and raises the possibility that NAFLD may not only be a marker but also an early mediator ofCVD. Expand
Importance of cardiometabolic risk factors in the association between nonalcoholic fatty liver disease and arterial stiffness in adolescents
TLDR
Nonalcoholic fatty liver disease (NAFLD) is only associated with increased arterial stiffness in the presence of the “high risk” metabolic cluster, which suggests that arterials stiffness related to the existence of NAFLD is predicated on the presenceof an adverse metabolic profile in adolescents. Expand
Non-Alcoholic Fatty Liver Disease, Insulin Resistance, Metabolic Syndrome and their Association with Vascular Risk.
TLDR
It is clear that NAFLD patients have a greater CV risk (independent or not) which needs to be addressed in clinical practice, and considerations that type 2 diabetes mellitus (T2DM) may be a common link betweenNAFLD/non-alcoholic steatohepatitis (NASH) and CVD. Expand
Association between non-alcoholic fatty liver disease and coronary calcification depending on sex and obesity
  • Seok-hyung Kim, Hae Yeul Park, +10 authors Hoon Young Choi
  • Medicine
  • Scientific Reports
  • 2020
TLDR
It is indicated that non-obese men with NAFLD are prone to coronary artery calcification (CAC), and that sex and obesity play a role in this association. Expand
Synergistic increase in cardiovascular risk in diabetes mellitus with nonalcoholic fatty liver disease: a meta-analysis
TLDR
It is suggested that NAFLD increases the risk of CVD in populations with comparable DM profiles, thereby reducing CVD morbidity and mortality. Expand
Nonalcoholic fatty liver disease associated with impairment of kidney function in nondiabetes population
TLDR
The most striking finding of this study is that NAFLD is negatively associated with kidney function, in nondiabetic population. Expand
Implication of liver enzymes on incident cardiovascular diseases and mortality: A nationwide population-based cohort study
TLDR
The unique pattern of association of ALT, AST, and GGT with the development of CVD and all-cause mortality in the Korean population was demonstrated, with GGT showing the most robust linear relationship with mortality before and after cardiovascular events independent of risk factors. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 42 REFERENCES
Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease.
TLDR
NAFLD is a strong predictor of cardiovascular disease and may play a central role in the cardiovascular risk of MS, and simultaneous inclusion of NAFLD and MS in a multivariate model revealed that NA FLD but not MS retained a statistically significant correlation with cardiovascular disease. Expand
Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon?
TLDR
Non-alcoholic fatty liver disease, especially in its more severe forms, is linked to an increased risk of CVD, independently of underlying cardiometabolic risk factors, which suggests that NAFLD is not merely a marker ofCVD, but may also be actively involved in its pathogenesis. Expand
Aminotransferase levels and 20-year risk of metabolic syndrome, diabetes, and cardiovascular disease.
TLDR
Both normal and increased levels of ALT are associated with long-term development of multiple metabolic disorders, indicating the potential for ALT values as biomarkers for the risk of metabolic disease. Expand
Elevated alanine aminotransferase levels predict mortality from cardiovascular disease and diabetes in Koreans.
TLDR
Elevated alanine aminotransferase (ALT) levels, as a marker for NAFLD, may serve as a surrogate predictor of CVD- or diabetes-related mortality among the Korean population. Expand
Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients.
TLDR
In conclusion, NAFLD is significantly associated with a moderately increased CVD risk among type 2 diabetic individuals and is independent of classical risk factors and is only partly explained by occurrence of metabolic syndrome. Expand
Body Fat Distribution, Liver Enzymes, and Risk of Hypertension: Evidence From the Western New York Study
TLDR
The association between GGT and hypertension is not caused solely by alcohol consumption and indicate that serum GGT, within its normal range, may predict hypertension among individuals with increased central fat distribution, suggesting that fatty liver may represent an important underlying mechanism for this association. Expand
Obesity and nonalcoholic fatty liver disease: Biochemical, metabolic, and clinical implications
TLDR
It is not clear whether NAFLD causes metabolic dysfunction or whether metabolic dysfunction is responsible for IHTG accumulation, or possibly both, but it is likely that abnormalities in fatty acid metabolism are key factors involved in the development of insulin resistance, dyslipidemia, and other cardiometabolic risk factors associated withNAFLD. Expand
Gamma-Glutamyltransferase Is Associated With Incident Vascular Events Independently of Alcohol Intake: Analysis of the British Women’s Heart and Health Study and Meta-Analysis
TLDR
GGT is associated with incident vascular events independently of alcohol intake, and the mechanisms underlying this association remain unclear and require future study. Expand
Alanine aminotransferase, gamma-glutamyltransferase, and incident diabetes: the British Women's Heart and Health Study and meta-analysis.
TLDR
Findings are consistent with the role of liver fat in diabetes pathogenesis, and suggest that GGT may be a better diabetes predictor than ALT, but additional studies with directly determined liver fat content, AlT, and GGT are needed to confirm this finding. Expand
Suspected Nonalcoholic Fatty Liver Disease and Mortality Risk in a Population-Based Cohort Study
TLDR
Suspected NAFLD in the 45–54 age group is a strong independent risk factor for cardiovascular death and warrants further cardiovascular risk management guidelines. Expand
...
1
2
3
4
5
...